USPTO Patent Grants - Therapeutics (A61P)

Anti-follicle stimulating hormone receptor antibodies and methods of treatment

USPTO granted Patent US12595293B2 to The Wistar Institute covering isolated antibodies and antigen-binding fragments that specifically bind to Follicle Stimulating Hormone Receptor (FSHR), along with methods for treating diseases by administering these antibodies. The patent includes 14 claims and covers compositions for cancer treatment applications.

Dosing regimes for treatment of synucleinopathies

USPTO granted patent US12595295B2 to Prothena Biosciences Limited covering antibody dosing regimes for treatment of synucleinopathies. The patent specifies intravenous antibody dosing of 3000-5000 mg or 1300-1700 mg every 3-5 weeks. This grant provides exclusive intellectual property rights for these therapeutic dosing protocols.

6-Thio-dG Treatment for Pediatric Brain Tumors

The USPTO granted Patent US12594293B2 to The Board of Regents of The University of Texas System on April 7, 2026, covering the use of 6-thio-dG (a telomerase substrate precursor analog) to treat therapy-resistant telomerase-positive pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. Inventors Jerry Shay and Rachid Drissi developed methods demonstrating that 6-thio-dG induces telomere dysfunction-induced foci, genomic DNA damage, cell death, and tumor growth delay in xenograft models.

Probiotics to prevent cognitive dysfunction

USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.

Cisplatin-Eugenol Analogue for Cancer Treatment

The USPTO granted Patent US12594338B2 to King Faisal Specialist Hospital & Research Centre for a cisplatin-eugenol compound with anti-cancer properties. The patent covers the compound composition, synthesis method, pharmaceutical formulations, and methods of cancer treatment. Inventors include Abdelilah Aboussekhra, Ibrahim Al-Jammaz, Basem Al-Otaibi, and Noura N. Alraouji. The patent was filed on July 27, 2023.

Exosome Production Method for Cancer Therapeutic Delivery

USPTO granted patent US12594344B2 to China Medical University for a large-scale exosome production method using cyclic tensile bioreactors. The patent covers exosomes with anti-HLA-G protein configured as delivery vehicles for cancer therapeutic agents. The grant includes 10 claims and applies to A61P 35/00 (antineoplastic agents) and related CPC classifications.

Nanoparticulate drug delivery for therapeutic applications

The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.

Topiramate oral liquid suspension patent granted

USPTO granted patent US12594241B2 to inventors Paul Sudhakar and Scott Boyer for an oral liquid suspension formulation containing topiramate (Application No. 18462651). The patent contains 29 claims covering the composition and methods of medical treatment using the formulation. Generic and branded pharmaceutical manufacturers should assess this patent for potential freedom-to-operate implications.

HIV Oral Drug Composition Patent

The USPTO granted Patent US12594244B2 to Gilead Sciences, Inc. covering a solid oral dosage form combining tenofovir alafenamide, emtricitabine, and a compound of Formula I for HIV treatment. The patent contains 29 claims and was granted on April 7, 2026, with a filing date of September 29, 2025.

siRNA Septicemia Treatment Patent

USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. covering an siRNA therapeutic targeting the kininogen (KNG) gene for treating septicemia. The patent includes 8 claims for the nucleic acid composition, pharmaceutical formulation, and siRNA conjugate. This is a standard patent grant公告 with no regulatory compliance obligations.

Vanda patents trichostatin A cancer treatment method

USPTO granted patent US12590162B2 to Vanda Pharmaceuticals Inc. covering a method of treating cancer using trichostatin A (TSA). Inventors include Mihael H. Polymeropoulos, Louis William Licamele, and Christian Lavedan. The patent contains 5 claims.

Fusion antibody for presenting antigen-derived T cell epitope

USPTO granted Patent US12590156B2 to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a fusion antibody composition designed to deliver viral antigen-derived CD8+ T cell antigen epitopes to target cell cytoplasm for presentation on major histocompatibility complex class I (MHC-I) molecules. The patent contains 22 claims covering the composition and its use in antigen presentation.

Polymorph of EP4 receptor antagonist, preparation method and use

USPTO granted patent US12590103B2 to Shanghai Yuyao Biotech Ltd. for a stable polymorph of an EP4 receptor antagonist. The patent covers the solid-state form with improved stability over the amorphous compound, with claims directed to oncology, immunology, and bone disease applications.

Gilead PD-1/PD-L1 inhibitors, cancer treatment compounds

USPTO granted Gilead Sciences, Inc. Patent US12590062B2 for PD-1/PD-L1 inhibitor compounds for cancer treatment. The patent covers compounds according to formula (I), methods of using said compounds singly or in combination with additional agents, and compositions for treating cancer. Application No. 17098171 was filed November 13, 2020, and the patent contains 18 claims.

Crystalline acetylcholinesterase inhibitor forms A, B, C for neurodegenerative diseases

USPTO granted Patent US12590061B2 to Shanghai Institute of Materia Medica, Chinese Academy of Sciences covering crystalline forms A, B, and C of an acetylcholinesterase inhibitor compound (2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1-indanone). The patent, filed November 24, 2020 as Application No. 17780449 with 10 claims, protects the stable, low-hygroscopicity crystalline forms used for preventing and treating neurodegenerative diseases.

Use of D9-methadone for postoperative pain relief

USPTO granted Patent US12590054B2 to the Board of Regents, The University of Texas System, covering the use of d9-methadone as an alternative formulation for methadone with improved pharmacokinetic properties for postoperative pain relief. The patent includes 15 claims and covers compositions and methods for managing pain following injury, disease, or surgery.

Benzimidazole and Benzimidazolone Based PROTAC Compounds for LRRK2 Degradation

The USPTO granted Arvinas Operations, Inc. patent US12589156B2 covering benzimidazole and benzimidazolone PROTAC compounds designed to recruit LRRK2 protein to E3 ubiquitin ligase for targeted degradation. The patent contains 12 claims and was filed on March 24, 2025.

GLP-1/GIP Dual Agonist Patent for Diabetes Treatment

USPTO granted patent US12589158B2 to Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. for long-acting GLP-1/GIP dual agonist compounds for treating Type II diabetes mellitus. The patent covers compounds with dual agonistic effects on glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors.

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Phenylethynyl-thiophene compounds for treating degenerative disorders

The USPTO granted patent US12589090B2 to Aquilus Pharmaceuticals, Inc. covering phenylethynyl-thiophene compounds that inhibit caspase 3 for treating degenerative disorders including ALS, Huntington's disease, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The patent claims 2 compounds and methods for their use.

Treatment of cachexia using fibroblast cells and products thereof

USPTO granted patent US12589119B2 to Fibrobiologics, Inc. covering methods and compositions for treating cachexia using immune-modulating fibroblasts. Inventors Pete O'Heeron and Thomas Ichim disclosed compositions including immune-modulating fibroblasts for treatment, amelioration, or prevention of cachexia or inflammation related to cachexia. The patent contains 12 claims.

Anaerostipes caccae Compositions for Treating Allergic and Autoimmune Diseases

USPTO granted Patent US12589122B2 to the University of Chicago on March 31, 2026, covering compositions and methods for treating infectious, autoimmune, allergic diseases, and food allergies using the bacterium Anaerostipes caccae. The patent includes methods for reducing allergic responses and preventing anaphylactic responses, with claims extending to compositions comprising the bacterium with prebiotics.

Bacteriophages for treatment of tuberculosis

USPTO granted Patent US12589127B2 to the University of Pittsburgh for pharmaceutical compositions comprising five or more bacteriophages designed to treat Mycobacterium tuberculosis infections. The patent covers methods of treating drug-resistant TB and preventing activation of latent TB disease, with 20 claims covering the phage combinations and treatment methods.

Aloe vera polysaccharide antimicrobial composition patent grant

USPTO granted Patent US12589130B2 to 2QR RESEARCH B.V. on March 31, 2026. The patent covers Aloe vera polysaccharide compositions with antimicrobial aggregating activity, having molecular weight of 30-100 kDa and comprising 80-100% w/w mannose. Inventors are Floris Koumans and Paul Kwakman. The patent has 14 claims.

Viral vectors with RDH12 coding regions for treating retinal dystrophies

The USPTO granted Patent US12589136B2 to The Regents of the University of Michigan covering viral vectors comprising RDH12 coding regions and methods of using such vectors to treat retinal dystrophies, including Leber Congenital Amaurosis. The patent, with 12 claims, names Debra A. Thompson, Robin R. Ali, and Alexander J. Smith as inventors. The patent covers nucleic acids encoding human RDH12 protein and their use in gene therapy applications for ophthalmological conditions caused by loss-of-function mutations.

Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof

The USPTO granted Patent US12589140B2 to The Brigham and Women's Hospital, Inc. covering methods for generating immune responses to cancer or infection by promoting differentiation of neutrophils into dendritic cells using GMCSF combined with immune complexes or anti-FcγRIIIB antibodies. The patent contains 14 claims and lists Tanya Mayadas, Vijaya Mysore, Xavier Cullere, and Jon C. Aster as inventors.

DNA Vaccine for Treating and Preventing Type 1 Diabetes

USPTO granted Patent US12589141B2 to The Fifth Medical Center of Chinese PLA General Hospital for a DNA vaccine using a B7-2-PE40 exotoxin fusion gene to treat Type 1 Diabetes. The patent, with 10 claims, covers reduction of blood glucose, restoration of insulin secretion, and reduction of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) levels. The application was filed on March 2, 2020.

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

Plasma kallikrein inhibitor patent for ocular disorders

The USPTO granted BioCryst Pharmaceuticals patent US12589093B2 covering plasma kallikrein inhibitor compositions for treating ocular disorders. The patent claims avoralstat-based drug compositions delivered via suprachoroidal space injection. The patent contains 16 claims and names inventors Yarlagadda Babu, Viral Kansara, and Rick McElheny.

Glucocorticoid receptor modulator relacorilant with paclitaxel patent granted

USPTO granted patent US12589094B2 to Corcept Therapeutics Incorporated on March 31, 2026, covering methods of co-administering glucocorticoid receptor modulator relacorilant with paclitaxel by reducing paclitaxel dose to approximately half when used together. The patent addresses drug-drug interaction management, noting that despite in vitro predictions of 5-fold increased paclitaxel exposure, in vivo co-administration showed only 80% increase, enabling a safer combination therapy for treating cancers such as ovarian and pancreatic.

Ruxolitinib formulation for reduction of itch in atopic dermatitis

USPTO granted Patent US12589096B2 to Incyte Corporation on March 31, 2026. The patent covers a topical 0.75% or 1.5% ruxolitinib cream formulation administered two times per day for reducing itch in patients with atopic dermatitis. The patent includes 20 claims and names Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, and Jim Lee as inventors.

ALPHA-1062 Pharmaceutical Composition for Treating Traumatic Brain Injury

USPTO granted Patent US12589099B2 to Alpha Cognition Inc. for a pharmaceutical composition containing ALPHA-1062 (or salt thereof) for treating confirmed or suspected traumatic brain injury (TBI). The patent includes 27 claims covering transmucosal/intranasal administration methods and a multi-use dispenser configuration. The composition may be self-preserving and anti-microbial.

Regeneron cyclodextrin protein drug conjugates

USPTO granted patent US12589101B2 to Regeneron Pharmaceuticals for cyclodextrin protein drug conjugates used in treating proliferative diseases. The patent contains 41 claims and covers compounds, compositions, and conjugates with cyclodextrin-based linker-payloads. Inventors: Amy Han and William Olson. Filing date: June 10, 2022.

Injectable sustained-release formulations for treatment of joint pain and inflammation

USPTO granted patent US12589102B2 to FORDOZ Pharma Corp. covering injectable drug-loaded microspheres combining steroidal and non-steroidal anti-inflammatory drugs for sustained release. The patent also protects methods of making the microspheres and using them to treat rheumatoid arthritis and osteoarthritis. The patent contains 9 claims and names inventors Sydney Ugwu, James He, and Zengli Fu.

C2-C7 alkyl boronic acids as antimicrobial antiviral therapeutic compounds

USPTO granted patent US12589103B2 to Cornell University covering methods for treating bacteria and viruses using C2-C7 alkyl boronic acids to reduce growth and virulence. The patent, filed October 7, 2020, names inventors Kenneth W. Simpson, Shiying Zhang, and Michael Fischbach and contains 28 claims.

Diaminoguanidine derivative treats bacterial infections in farmed animals

USPTO granted patent US12589085B2 to Guangzhou Insighter Biotechnology Co., Ltd. for a diaminoguanidine derivative compound and feed composition for veterinary use in preventing and treating bacterial infections in farmed animals. The patent covers the compound with R1 as C1-C20 alkyl, applications including reproductive system and skin infections, and includes 11 claims.

USPTO Patent Grant for Viral Infection Compounds Targeting Sigma Receptors

The USPTO has granted a patent (US12582619B2) to Thomas Jefferson University for compounds that modulate Sigma receptors to treat viral infections. The patent covers methods for preventing, treating, or ameliorating viral infections using these compounds, potentially in combination with other therapeutic agents.

USPTO Grants Patent for Sodium Oxybate to Treat Idiopathic Hypersomnia

The United States Patent and Trademark Office (USPTO) has granted patent US12582622B2 to Jazz Pharmaceuticals Ireland Limited for methods of treating idiopathic hypersomnia with sodium oxybate. The patent is effective March 24, 2026.

USPTO Patent Grant: Composition for Improving Muscle Function

The USPTO has granted patent US12582623B2 to N.V. Nutricia for a composition comprising EPA, MA, and leucine. This composition is intended for the prevention and/or treatment of diseases involving muscle decline or for improving muscle function.

Nestle Patent for MCTs Improving Cognitive Function

The USPTO has granted Nestle a patent (US12582627B2) for MCT formulations designed to improve cognitive functions, such as memory and executive function, and to prevent or treat mild cognitive impairment (MCI). The patent specifies daily dosages and composition ratios of medium chain triglycerides, particularly octanoic acid.

USPTO Patent Grant: Dapansutrile for Breast Cancer Treatment

The USPTO has granted patent US12582628B2 to Olatec Therapeutics, Inc. for a method of treating breast cancer using dapansutrile, optionally in combination with a checkpoint inhibitor. The patent covers methods of treatment and has an effective date of March 24, 2026.

USPTO Patent Grant for Improving Kidney Function

The USPTO has granted patent US12582631B2 to Chinook Therapeutics, Inc. for methods of improving kidney function. The patent, which includes 36 claims, was filed on August 16, 2022, and granted on March 24, 2026.

USPTO Patent Grant for CAH Treatment Compound

The USPTO has granted patent US12582634B2 to Neurocrine Biosciences, Inc. for a compound and synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent covers specific chemical structures and their preparation, aiming to provide new therapeutic options for this condition.

USPTO Patent Granted for Cancer Treatment with ERK Inhibitors

The USPTO has granted a patent (US12582635B2) to Biomed Valley Discoveries, Inc. for methods of treating cancer with atypical BRAF mutations using ERK inhibitors. The patent covers compositions, methods for treatment, and identification of suitable patient populations.

Donepezil Topical Formulation Patent for Intradermal Use

The USPTO has granted a patent (US12582637B2) to Arctic Therapeutics HF for a topical formulation of donepezil intended for intradermal application. The patent covers compositions and methods of use for this specific formulation.

USPTO Grants Patent for Sulfur Compound in Tumor Treatment

The USPTO has granted patent US12582641B2 to SHANGHAITECH UNIVERSITY for a sulfur-containing compound based on a glutarimide skeleton and its application in treating tumors. The patent filing date was February 25, 2020, and the grant date is March 24, 2026.

USPTO Patent US12582642B2 for Treating Bovine Papillomatosis

The USPTO has granted patent US12582642B2 to KINOPHARMA, INC. for a composition and method to treat bovine papillomatosis. The patent covers compounds represented by Formula (I) or their pharmaceutically acceptable salts.

USPTO Patent Grant: Dopamine D3 Agonists for CNS Disorders

The USPTO has granted patent US12582648B2 to Bioprojet Pharma for a method of treating central nervous system disorders, including restless leg syndrome and neurodegenerative diseases, using dopamine D3 partial agonists. The patent details specific applications and classifications related to these therapeutic uses.

USPTO Patent for Hair Follicle Regeneration

The USPTO has granted Washington University a patent (US12582649B2) for compositions and methods for hair follicle regeneration using TRPV4 activating agents. The patent aims to treat hair loss conditions such as alopecia and telogen effluvium.

USPTO Grants Patent for Idiopathic Pulmonary Fibrosis Treatment

The USPTO has granted a patent (US12582653B2) to BEIJING TIDE PHARMACEUTICAL CO., LTD. for a compound and method to treat idiopathic pulmonary fibrosis. The patent covers compounds represented by formula (I) and their pharmaceutically acceptable derivatives.